Advanced Cell Technology (ACT) Inc. has filed in Europe for Orphan Drug Designation for its retinal epithelial (RPE) cells to treat Stargardt’s Macular Dystrophy (Stargardt’s Disease), according to a news release today.

If the treatment is approved by the European Medicines Agency, ACT would secure 10 years of marketing exclusivity for RPE cells taken from embryonic stem cells, certain fee reductions or waivers and free scientific advice.

SOURCE